Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Nov 20, 2025
Reporting period
Not applicable
Filed with the SEC
Nov 21, 2025
DirectorGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001193210-25-000009
Filed / recorded
Nov 21, 2025, 6:03 AM UTC
Added to OQRO
Oct 6, 2026, 7:59 PM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Jazz Pharmaceuticals plc
Issuer CIK
1232524
Ticker
JAZZ
Reporting person
Bruce C Cozadd
Relationship
Director
Security
Ordinary Shares
Table
Non-derivative (Table I)
Transaction date
Nov 20, 2025
Transaction code
A
Shares / units
2,506
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
393,332
Ownership form
Direct
Amendment
No
Footnotes from the filing
These restricted stock units are granted pursuant to the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan. Each restricted stock unit represents a contingent right to receive one ordinary share upon the vesting of the unit. Subject to the Reporting Person's continuous service and certain additional conditions, these units will vest in full on July 24, 2026.